Outsourcing Formulation Development & Manufacturing: CDMOs Are Making Their Supply Chains More Resilient & Secure

In a new article with Drug Development & Delivery on Outsourcing Formulation Development & Manufacturing, Dr Campbell Bunce, Chief Scientific Officer contributed to an article about how CDMOs like Abzena are making supply chains more resilient and secure.

Growing R&D activities, personalized medicines, large-scale production of biologics, and access to new technologies are some of the biggest reasons why the contract development and manufacturing organization (CDMO) market is expected to practically double from $168 billion this year to $318 billion by 2034.

At Abzena, we are reshaping our supply chain strategy to thrive in a complex global market. “In the current geopolitical landscape, and among recent discussions about tariffs on pharmaceutical products and the BioSecure Act, our fully integrated, US-based manufacturing model offers a strategic advantage, often delivering a 25% price edge over many international competitors,” says Dr. Campbell Bunce, Chief Scientific Officer of Abzena. “By leveraging domestic partners for sterile filling, lyophilization, and packaging, we effectively manage the entire supply chain from monoclonal antibody (mAb) production to final drug product within the United States. This approach helps us minimize the unknown risks posed by global trade shifts for our customers.”

Read the article in full here